- Home
- NRDS vs CERT Comparison
NRDS vs CERT Comparison
Compare NRDS & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRDS | CERT |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 720.4M | 860.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRDS | CERT |
|---|---|---|
| Price | $8.10 | $4.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $15.00 | $11.67 |
| AVG Volume (30 Days) | 992.9K | ★ 3.0M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.42 | ★ 87.50 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $836,600,000.00 | $418,838,000.00 |
| Revenue This Year | $10.13 | $4.18 |
| Revenue Next Year | $7.11 | $5.39 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | ★ 21.67 | 8.75 |
| 52 Week Low | $7.33 | $4.45 |
| 52 Week High | $16.24 | $13.88 |
Technical Indicators
Market Signals| Indicator | NRDS | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 31.69 | 27.23 |
| Support Level | N/A | N/A |
| Resistance Level | $11.22 | $6.47 |
| Average True Range (ATR) | 0.54 | 0.34 |
| MACD | -0.30 | -0.17 |
| Stochastic Oscillator | 21.43 | 8.23 |
Price Performance
Historical ComparisonAbout NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.